News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medtronic, Inc. (MDT), Johnson & Johnson (JNJ) Study Gains Put Diabetics Nearer to Artificial Pancreas


6/24/2013 8:08:42 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

A decade of work by scientists to create an artificial pancreas that will independently control insulin levels in people with Type 1 diabetes took a leap forward in research from Medtronic Inc. (MDT) and Johnson & Johnson. Medical pumps developed by the two companies were shown in separate studies this weekend at the American Diabetes Association meeting in Chicago to successfully sense changes in blood sugar levels and adjust insulin delivery accordingly. Type 1 diabetes occurs when insulin-releasing beta cells in the pancreas are destroyed. Patients must test their blood repeatedly with finger sticks or a glucose monitor, then inject themselves with the hormone using a needle or pump to control blood sugar. The emerging artificial pancreas technology seeks to link a glucose monitor, or sensor, to a pump that delivers insulin on its own as needed, mimicking a healthy pancreas.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at Reuters
Read at Red Orbit
Read at Zee News

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES